This is a pilot study which will enroll 5 patients over 2 years, prospectively. Our hypothesis is that bortezomib will effectively target plasma cells and successfully treat refractory autoimmune cytopenias. This will be a relevant study as it will be the first step in establishing a novel therapeutic modality and potentially reducing length of hospitalization and degree of immune suppression for refractory autoimmune cytopenias.